This compares with a 32% rise for LLY stock, partly aided by hopes for regulatory approval for its Alzheimer's treatment – Donanemab – which, if approved, will be a multi-billion dollar opportunity for Eli Lilly. However, there is more to the comparison. Let's step back to look at the fuller picture of the relative valuation of the two companies by looking at historical revenue growth as well as operating margin growth. Our dashboard Abbott vs Eli Lilly : Similar Market Cap; Which Stock Is A Better Bet? has more details on this.